SCHEMBL3014594

SCHEMBL3014594

Cc1cccc(-c2csc(N3CCN(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)n2)c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
ALDH1A1 P00352 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
MAPK1 P28482 2/20 0.45
LMNA P02545 3/20 0.44
THRB P10828 1/20 0.43
TP53 P04637 1/20 0.43
HSD11B1 P28845 2/20 0.42
POLB P06746 2/20 0.42
AR P10275 2/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017471 0.92 SMN1; SMN2 (0.52) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3015947 0.92 ALDH1A1 (0.52) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3006370 0.90 MAPT (0.47) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3015386 0.90 SMN1; SMN2 (0.53) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3015735 0.89 MAPT (0.48) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3017647 0.89 VCAM1 (0.51) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3017444 0.89 ALDH1A1 (0.52) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3017308 0.88 L3MBTL1 (0.55) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3010696 0.86 MAPT (0.47) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3010061 0.86 ALDH1A1 (0.54) MAPTUSP2RECQLHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.